# To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)

> **NCT00537537** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 100 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Telbivudine

## Key facts

- **NCT ID:** NCT00537537
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-06
- **Final completion:** —
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537537, "To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00537537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*